FDA ODAC Briefing Document NDA[removed]Olaparib

First Page		Document Content
Oncology Olaparib Ovarian cancer BRCA mutation Gemcitabine Breast cancer End point of clinical trials Medicine Organofluorides Chemistry		FDA ODAC Briefing Document NDA[removed]Olaparib Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 509,78 KB Share Document on Facebook

	Profiling of mass spectrometry data for ovarian cancer detection using negative correlation learning Shan He, Huanhuan Chen, Xiaoli Li, and Xin Yao The Centre of Excellence for Research in Computational Intelligence and DocID: 1vn3H - View Document
	Case study for data visualiza1on using NaviCell Data Visualiza1on Web Service TCGA Ovarian cancer samples Map: Mast cell network DocID: 1velf - View Document
	For personal use only BARD1 ANNOUNCES POSITIVE RESULTS FROM OC-400 STUDY OF BARD1-OVARIAN TEST • Successful completion of OC-400 Study to evaluate the accuracy of BARD1-Ovarian for detection of ovarian cancer using th DocID: 1ve2D - View Document
	Commentary Long-term breast cancer risk following ovarian stimulation in young egg donors: a call for follow-up, research and informed consent Jennifer Schneider a,*, Jennifer Lahl b, Wendy Kramer c DocID: 1v7BC - View Document
	Clinical Guideline Annals of Internal Medicine Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement DocID: 1uqkO - View Document